Sky Labs' Wearable Device "Apollon" Recognized as an Honoree in CES 2025 Innovation Awards

November 18, 2024 11:00 AM AEDT | By Cision

Sky Labs' Wearable Device — Image source: Kalkine Media

Recent News

RBA Rate Cut on the Horizon? Economic Shifts Set the Stage for May Dec...

Himel Celebrates Resounding Success at 2025 Global Distributor Confere...

ASX Rally Fueled by Healthcare and Uranium Momentum

Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indication...

SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Sky Labs announced that its groundbreaking wearable device, Apollon, has been named an "Honoree" in the Artificial Intelligence category at the CES 2025 Innovation Awards. Hosted by the Consumer Technology Association (CTA)®, the CES Innovation Awards program annually recognizes outstanding achievements in design and engineering across 33 categories of consumer technology. This prestigious honor marks Sky Labs' second award at CES, underscoring the company's continued impact on health technology innovation.

CART BP pro(left) and Wearable Device ‘Apollon’ (right, project name)

Apollon is a pioneering wearable device designed for comprehensive monitoring of vital health indicators. Integrating both a wrist-worn module and a ring-type sensor, Apollon automatically and periodically measures SpO₂, irregular pulse, pulse rate, blood pressure, respiration rate, and skin temperature, while also offering on-demand body temperature measurements. Engineered with hospitalized patients in mind, Apollon supports extensive tracking of health data, providing valuable insights for health monitoring and treatment.

Apollon's innovative design includes a wrist-worn control module with an integrated monitor and a detachable ring-type sensor module, connected seamlessly for optimal user experience. The wristband is crafted from silicone, promoting hygienic use and enabling secure attachment and removal from the control module. Additionally, the single-sized silicone ring around the sensor module provides comfort and adaptability, allowing users of varying finger sizes to wear the sensor comfortably for extended periods. The hardware is streamlined with power, charging, and data transmission connectors on a single surface, optimizing its structure for enhanced ease of use.

In parallel with Apollon's success, Sky Labs' CART BP pro, a ring-type ambulatory blood pressure monitoring device, has been selected as the primary monitoring tool for an ambitious five-year cohort study led by the Korean Society of Hypertension, in celebration of their 30th anniversary. This large-scale CUFFLESS BP Registry-Outcome Study will incorporate CART BP pro to further research into innovative hypertension management strategies. The study aims to evaluate a range of clinical outcomes associated with hypertension and to explore advanced, non-invasive solutions for blood pressure management.

About Sky Labs
Founded in September 2015, Sky Labs is a leading healthcare startup that has developed CART (Cardio Tracker), a ring-shaped medical device designed for disease monitoring using heart signals collected through optical sensors. Following this, the company developed CART BP, a cuffless, ring-shaped device that enables continuous 24-hour blood pressure monitoring, providing valuable treatment information and making a groundbreaking contribution to improving the quality of life for hypertension patients. Sky Labs has signed an exclusive domestic distribution agreement for CART BP with South Korea's Daewoong Pharmaceutical and is preparing for nationwide sales to hospitals, clinics, and general consumers.

Media Inquiries
Edelman Korea [email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.